Avaliação do potencial probiótico do lactobacillus plantarum CNPC003 e lactobacillus mucosae CNPC007 em modelo de inflamação intestinal em animais

Abstract

Inflammatory Bowel Disease (IBD), characterized by presenting an uncontrolled chronic infection in the intestinal mucosa, England, mainly, two pathologies: Ulcerative Colitis (UC) and Crohn's Disease (CD). In these, the local immune system remains actively activated and the chronic intestine is inflamed due to an inability to decrease inflammatory responses. The production and release of reactive oxygen species (ROS) and pro-inflammatory cytokines by phagocytes play an important role in the pathophysiology of IBD. Therapeutic failures and adverse effects on the drug arsenal of choice, encouraged by researchers to study alternative methods of controlling the intestinal inflammatory process, among which they can be used as probiotics. Thus, this research aimed to evaluate the intestinal anti-inflammatory activity of the pretreatment with probiotics Lactobacillus plantarum CNPC003 (LP) and Lactobacillus mucosae CNPC007 (LM) in the experimental colitis model induced by dinitrobenzenesulfonic acid (DNBS) in rats. Thus, Wistar rats were divided into 5 groups of experiments (n = 7): Healthy group: Healthy (S) that received saline solution; Collitic groups: DNBS control (DNBS) that received saline solution; and clinical examinations with probiotics: LP, LM and standard drug sulfasalazine (SSZ) at a dose of 250 mg / kg. The pre-defined tests for each group were administered by gavage for 17 days before induction of intestinal inflammation. After the procedures, on the 17th day, a colitis was induced by intracolonic administration of 30 mg of DNBS (50% ethanol, v / v) and then as continued administrations until the 19th day. On the 20th day, seventy-two hours after induction, all animals were euthanized. Macroscopic, microscopic, inflammatory markers were regulated such as myeloperoxidase (MPO), induced nitric oxide synthase (iNOS), metalloproteinase-9 (MMP-9), a nuclear B signaling pathway (NF-κB) and as a cytokine factor of necrosis-α tumor (TNF-α), interleukin-10 (IL-10), interleukin-β (IL-1β), interleukin-17 (IL-17), oxidative stress (malondialdehyde) and with mucin intestinal barrier integrity -2 (MUC-2), occlusion zone-1 (ZO-1) and ocludine (OCL). Pre-treatment with probiotics was able to attenuate the severity of the colonic damage caused by DNBS, observed in the reduction of the macroscopic damage score (p <0.05 vs. DNBS). This effect was associated with a reduction activity of MPO, MMP-9 and iNOS (p <0.05 vs. DNBS) and in the levels of pro-inflammatory cytokines TNF-α, IL-1β and IL-17 (p <0 , 05 vs. DNBS). On the other hand, probiotics increased electronic levels of IL-10, well known as an antiinflammatory cytokine. The beneficial effect of the probabilities of DNBS-induced intestinal infection was also demonstrated by the ability to reduce colonic oxidative stress, observed by the reduction in mood disorders (MDA) (p <0.05 vs. DNBS). Additionally, LP increased the expression of markers involved in epithelial integrity such as OCL and ZO-1, while LM increased the expression of OCL, MUC-2 and ZO-1 (p <0.05 vs. DNBS). Thus, the probiotics LM and LP stand out for presenting an intestinal anti-inflammatory potential that can be an alternative in the prevention of IBD.